US$21m for microbiome therapies

Scottish biopharmaceutical company EnteroBiotix is focussed on addressing a wide range of diseases by enhancing the diversity of the microbiome. Now, this approach has found new backers: A investor consortium led by Thairm Bio have put US$21m into the Glasgow-based company. Investors also include Kineticos Ventures as well as existing investors Scottish Enterprise and SIS Ventures.

The money will go toward EnteroBiotix’ pipeline of microbial therapeutics developed to enhance the gut microbiome. The company is hopeful that their products will have applicability across multiple disease areas. In addition to advancing its product pipeline, the company also plans to grow its headcount to around 50 as well as expand its leading GMP manufacturing and analytical capabilities.

“This successful financing round is a strong endorsement of our pioneering microbiome approach.” commented EnteroBiotix CEO James McIlroy. “It gives significant momentum to our mission to transform the lives of patients through novel orally delivered medicinal products that enhance the gut microbiome. We are determined to change the standard of care for patients battling debilitating diseases associated with the microbiome.”